Evidence map›Paper›PMID 23881648›Full record

ReviewChemMedChem2013

The cell's nucleolus: an emerging target for chemotherapeutic intervention.

Amanda J Pickard, Ulrich Bierbach

Open access · greenAbstract readReview
In one paragraph

Review in ChemMedChem, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Analysis ofPharmaceuticals (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Review
  5. Article
  6. Novel role of the dietary flavonoid fisetin in suppressing rRNA biogenesis.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  7. Article
  8. Article
  9. Nucleolar Stress Induction by Oxaliplatin and Derivatives.Journal of the American Chemical Society · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amanda J PickardDepartment of Chemistry, Wake Forest University, Winston-Salem, NC 27109, USA.
Ulrich Bierbach
Wake Forest University · US

Funding

Novel DNA-metalating Hybrid Anticancer AgentsR01CA101880 · NCI · WAKE FOREST UNIVERSITY · PI BIERBACH, ULRICH · 2003 to 2012
$1.8M
NCI NIH HHS CA 101880NCI NIH HHS R01 CA101880
6 · The paper itself

Abstract

The transient nucleolus plays a central role in the up-regulated synthesis of ribosomal RNA (rRNA) to sustain ribosome biogenesis, a hallmark of aberrant cell growth. This function, in conjunction with its unique pathohistological features in malignant cells and its ability to mediate apoptosis, renders this sub-nuclear structure a potential target for chemotherapeutic agents. In this Minireview, structurally and functionally diverse small molecules are discussed that have been reported to either interact with the nucleolus directly or perturb its function indirectly by acting on its dynamic components. These molecules include all major classes of nucleic-acid-targeted agents, antimetabolites, kinase inhibitors, anti-inflammatory drugs, natural product antibiotics, oligopeptides, as well as nanoparticles. Together, these molecules are invaluable probes of structure and function of the nucleolus. They also provide a unique opportunity to develop novel strategies for more selective and therefore better-tolerated chemotherapeutic intervention. In this regard, inhibition of RNA polymerase-I-mediated rRNA synthesis appears to be a promising mechanism for killing cancer cells. The recent development of molecules targeted at G-quadruplex-forming rRNA gene sequences, which are currently undergoing clinical trials, seems to attest to the success of this approach.

Indexed as

Antineoplastic AgentsApoptosisCell NucleolusDNAHumansNeoplasmsRNA, RibosomalTranscription, GeneticAntineoplastic AgentsDNARNA, Ribosomalantitumor agentsapoptosisDNA targetingp53ribosome biogenesis

Identifiers

PMID23881648
PMCPMC3893319
OpenAlexW1985698480

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.